Kornimate/medical-research-clean huggingface dataset:
effects of angiotensin ii receptor blocker compared with diuretics in high-risk hypertensive patients

Conditions: Essential Hypertension

Summary: the aim of the study is to investigate the optimized treatment strategy of hypertension, so as to make more patients to reach the blood pressure goals and to reduce cardio-cerebrovascular events. objective and methods: patients are eligible for inclusion in the study if they are essential hypertension, 50-79 years of age with at least one cardiovascular risk factor and sign the informed consent forms. this project is a multi-centre, prospective randomized,，openlabel blind-endpoint evaluation controlled (probe) trial. 12000 patients will be randomly assigned to either of low-dose amlodipine+telmisartan group or amlodipine+ diuretics group. among those patients with serum cholesterol between 4.0-6.1mmol/l, they will be also randomized into small dose of statin-based regimen or standard management regimen; patients will also randomly assigned to intensive lifestyle intervention group or standard intervention group according to the community area where the patients in.

this study is aimed to observe the main outcome (stroke, myocardial infarction and death from cardiovascular disease) differences between different groups.

Eligibility criteria:
inclusion criteria: * essential hypertension * 50-79 years old * with at least one of the cardiovascular risk factor * sign consent forms exclusion criteria: * secondary hypertension * attack of cerebrovascular events or myocardial infarction within recent 3 months * coexistence of severe cardiomyopathy, rheumatic or congenital heart diseases * unstable angina * severe hepatopathy or nephropathy (alt elevation \> 2 fold or serum creatinine \> 2.5mg/dl) * malignant tumor * gout * women taking contraceptives or with pregnancy * allergic history to the research drugs * validated contradiction to the research drugs * participating in other clinical trials * unable for long-term follow-up or poor compliance * unsuitable for clinical trial at the discretion of doctors in charge

Keywords: hypertension cardiovascular risk factors drugs intervention lipid-lowering therapy 50-79 years of age sign the informed consent forms
study of the safety of mri scans in people who have breast tissue expanders after mastectomy

Conditions: Breast Cancer; Breast Neoplasms; Breast Adenocarcinoma

Summary: the purpose of this study is to find out whether it is safe to perform mri scans in people who have breast tissue expanders in place.


Eligibility criteria:
patients with breast tissue expanders that require an mri for clinical purposes are eligible for this study. patients must provide an implant card or surgical report indicated the exact make and model of their implanted tissue expander. breast tissue expanders marked as "mri unsafe" will be allowed with exceptions as described in the participant exclusion criteria. while all types of mri will be included in this study, including breast mri, we anticipate that most of the mri examinations ordered will evaluate the brain or spine for detecting or following metastasis. inclusion criteria: * patient ≥ 18 years old on day of signing informed consent * has a breast tissue expander implanted \> 28 days ago * patients must provide an implant card or surgical report indicated the exact make and model of their implanted tissue expander exclusion criteria: * patients with aeroform tissue expanders (manufactured by airxpanders) * anyone who would normally be excluded from undergoing an mri examination as per the memorial hospital for cancer and allied diseases screening policy in the mri safety policy (https://one.mskcc.org/sites/pub/ehs/policies/ecse-2009.pdf), aside from having a breast tissue expander * patients who are reportedly pregnant, who have a positive urine or serum pregnancy test at the time of imaging, or for which pregnancy cannot be ruled out. * patients who are unable to tolerate, comply or complete the mri exam due to claustrophobia, anxiety, known psychiatric or substance abuse disorder, age, frailty, or medical instability.

Keywords: breast tissue expander breast cancer mastectomy 21-055 memorial sloan kettering cancer center
erbium chromium: ysgg laser effect on surgical treatment of chronic periodontitis

Conditions: Generalized Chronic Periodontitis

Summary: microbiological and clinical assessment of er,cr:ysgg laser in conjunction to open flap debridement (ofd) in treatment of chronic periodontitis through real time pcr assay for quantification of total bacterial load.

two groups are randomly allocated (random number generation) by microsoft excel into two groups : 1. group (1) open flap debridement (ofd) surgery after conventional periodontal therapy (scaling \&curettage and root planing) combined by er,cr:ysgg laser assisted pocket therapy (elapt) which will be applied to pocket epithelial lining and root surface. 2. group (2) open flap debridement (ofd) surgery after conventional periodontal therapy (scaling \&curettage and root planing) will be performed.

Eligibility criteria:
inclusion criteria: * patients are diagnosed to have chronic periodontitis, having infrabony posterior periodontal pocket measuring 5 mm or more. * female or male. * 25 - 55 years. * medically controlled according to medical coding of review of systems . * patient without history of drug administration in last month . exclusion criteria: * tobacco smoking. * pregnancy. * patients not follow periodontal hygienic instructions. * patients under any medication that affect periodontal healing. * the presence of any systemic disease that affect periodontal healing.
trigeminal brainstem mapping

Conditions: Headache Disorders, Primary; Migraine

Summary: to what extent the somatotopy of the 3 branches of the trigeminal nerve (v1,v2,v3) as well as the greater occipital nerve (gon) in the brainstem but also in the thalamus and the insula can be mapped using functional imaging and bold in humans is not known but might play an important role in imaging headache diseases. the aim is to map their somatotopy by random stimulation of v1, v2, v3 and the gon with painful electrical input during acquisition of bold-fmri.


Eligibility criteria:
inclusion criteria: * healthy * suitable fo mri exclusion criteria: * headache disease * psychological disorder * pregnancy * all exclusion criteria necessary for imaging in a 3 t mri scanner
novel cooling device for the elimination of warm ischemia during renal transplantation

Conditions: Kidney Transplant; Complications; Delayed Graft Function

Summary: avoiding warm ischemia time during vascular anastomosis of the renal allograft is important to prevent damage. the investigators are studying a cooling device that may control the temperature of the renal allograft during transplant surgery; attempting to keep temperatures at or below 5°c for at least 60 minutes. if found effective, this could eliminate warm ischemia and potentially prevent damage to transplanted kidneys.

warm ischemia can damage a renal allograft in many different ways often leading to early failure of the kidney transplant and sometimes even death of the transplant recipient. for this reason every effort is made to keep the allograft cold during the removal and transportation, and protocols have been developed to ensure this. although kidneys are kept below 5°c during transportation, they re-warm rapidly during the transplant surgery. on average, kidneys are exposed to 40 or more minutes of dangerously warm temperatures during transplant surgery. to avoid damage, it is important to reduce the amount of time it is exposed to warm temperatures. currently, there are no devices or standardized protocols available to ensure a kidney stays cold during the transplant surgery. the principal investigator has developed kidney skinn, a device that may control the temperature of the renal allograft during transplant surgery; keeping allograft temperatures at or below 5°c for at least 60 minutes. if found effective, this could eliminate warm ischemia and potentially prevent damage to transplanted kidneys. the device may also potentially provide retraction and support for the kidney during the transplant operation, making the surgery easier to perform. additionally, the device may be found to be easily removed once the transplant is complete. a previous study was conducted with the kidney skinn in animals; the next step is to investigate whether the device can perform in the human clinical setting. this study will be done in 2 steps. part a: a series of consecutive consenting patients to determine device initial safety, and part b: a single-centre randomized-controlled pilot study of kidney transplant recipients.

Eligibility criteria:
inclusion criteria: 1. ≥18 years of age at time of transplant 2. slated to receive a single cadaveric organ 3. donor declared by traditional neurological determination of death (ndd) 4. standard criteria donor (scd) or extended criteria donor (ecd) 5. consent obtained prior to the transplant operation exclusion criteria: 1. living donor (ld) 2. donor after cardiocirculatory death (dcd) 3. highly sensitized patients (those with panel-reactive antibody or pra \>80%) 4. recipient of a previous kidney transplant

Keywords: kidney transplant warm ischemia time delayed graft function vascular anastomosis renal hypothermia
reclaim: recovering from covid-19 lingering symptoms adaptive integrative medicine

Conditions: Long COVID; Post COVID Condition; Post Acute Sequelae of COVID-19

Summary: the researchers propose to develop a canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of covid-19 ("long covid"). participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions. because this is an adaptive trial, arms can be dropped if found to be ineffective and new arms can be added. interventions will last for 2 months and participants will be followed for an additional 4 months (6 months total). approximately 800-1000 patients with long covid will be recruited across canada. results from this trial will accelerate the availability of high-quality, real-time evidence and solutions to enable canada to improve the clinical care of patients with long covid.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. positive covid-19 test by nasopharyngeal swab rt-pcr (reverse transcription polymerase chain reaction) test, antibody or antigen tests at least 3 months prior to randomization; or presumed covid-19 assessed by the site investigator (no positive covid-19 test) with acute illness after october 15, 2019. 3. patients should be treated with standard of care therapies (as discussed in the study manual) for at least 4 weeks prior to entry into trial. 4. lingering covid-19 symptoms beyond 3 months from onset of acute covid and symptoms have lasted at least 2 months. the onset of covid is considered the earliest of two dates: the date of positive test or the date of first symptoms; 5. lingering symptoms from covid-19 present at the time of randomization. 6. female patients of childbearing potential (as assessed by the overseeing investigator) who are sexually active must agree to practice true abstinence or use effective methods of contraception while on study treatment. effective methods of contraception must be discussed and approved by the overseeing investigator. 7. must be able to provide informed consent and both willing and able to comply with study requirements. exclusion criteria: 1. patients who had mechanical ventilation or extracorporeal membrane oxygen (ecmo) for covid-19; 2. current end-organ failure, organ transplantation, or current hospitalization in acute care hospital; 3. contraindications to all of the study interventions; 4. co-enrolment in another interventional trial (co-enrolment in an observational study is permitted); 5. currently pregnant or breastfeeding.
predicting functional outcome and response to therapy of anti-nmdar encephalitis at diagnosis

Conditions: Anti-NMDA (N-Methyl D-Aspartate) Receptor Encephalitis

Summary: the goal of this international cohort study is to develop a prediction model for long-term outcome and response to first-line immunotherapy of anti-nmdar encephalitis, already at the moment of diagnosis.

anti-nmdare is a severe, but treatable neurological condition, with considerable and variable long-term disability. the previously developed anti-nmdar encephalitis one-year functional status (neos) score predicts outcome a month into treatment. to predict outcome and response to immunotherapy at the time of diagnosis would be a serious improvement. this would timely identify patients in need for aggressive treatment and avoid harmful side-effects in those with good outcome. international data from five anti-nmdar encephalitis cohorts will be combined to attain these goals. the investigators strive to have less than 10% missing data on all variables and will impute data were needed. the datasets will then be split - with equal distributions of cohorts and good/poor outcome - to develop (70%) and validate (30%) the neos2 model. the primary outcome is functioning one year after diagnosis. a secondary analysis is targeted to predict the effect of first-line therapy. potentially relevant predictive variables are identified with a univariable analysis on the original data, confirmed with backwards selection on the imputed datasets. after checking for multicollinearity and linearity of the variables, identified variables are added to a mixed effects logistic regression model on the original and imputed datasets, to identify the final set of predictive variables. to make the models opportune for daily medical practice, the investigators will assign points to (categories of) the included variables, based on the coefficients.

Eligibility criteria:
inclusion criteria: * diagnosed with anti-nmdar encephalitis (according to the graus criteria) exclusion criteria: * preceding herpes simplex encephalitis * premorbid dependency (modified rankin scale \> 2)

Keywords: prognosis immunotherapy
covid19 and physical and emotional wellbeing of hcp

Conditions: Mental Health

Summary: the current covid-19 pandemic has affected more than 3 million people worldwide across more than 200 countries. in the united kingdom alone, at the end of april, there were almost 160,000 confirmed cases with more than 20,000 deaths. this has undoubtedly had significant physical and economical impact on the public. healthcare workers are at high risk of developing life-threatening infectious diseases with increased exposure to patients' blood and bodily fluids. as such, health care workers arguably experience heightened anxiety and are predisposed to greater negative psycho-social impact from the current covid-19 pandemic. the aim of this study is to evaluate the physical and psychological impact of covid-19 on healthcare workers. this will be performed in two phases. in phase 1, investigators will collect information to evaluate the current psychiatric symptom profile (in particular, screening for anxiety or depression related symptoms), alcohol use, sleep-related complaints and overall well-being among healthcare workers who participate in this survey (with a focus on junior doctors). in addition the association of these mental health and behavioural parameters with the prevalence of stressful occasions, such as long-hours, unpredictability of work / redeployment, availability of personal protection equipment and concerns regarding family/relationship and self will be assessed. in phase 2, investigators will then reassess for the development or progression of psychiatric symptoms, use of alcohol and other substances, behavioural or interpersonal relationship changes as well as physical well-being at 6 weeks and 4- months. physical well-being is assessed through the presence of suspected or confirmed covid-19 infection and absence from work. specifically, investigators will study the impact of variable provision of personal protection equipment (supply and training), extended working hours, and concern for well-being of family members, on work morale and anxiety levels. another aim is also study the longer term mental health consequences of the current pandemic on health care workers.


Eligibility criteria:
inclusion criteria: 1. aged \>=18 2. electronic consent 3. either: a - healthcare workers in contact with patients with confirmed or suspected covid-19 b - healthcare staff not having direct patient contact c - non-healthcare academic staff with no direct patient contact exclusion criteria: 1. age\<18 2. individuals not belonging to the 3 cohorts of interest listed in the inclusion criteria. 3. those who are not able to understand written english will be excluded, indeed by the design and methodology of the study, as the study invite and all other information provided is in english.

Keywords: healthcare professionals personal protective equipment covid-19 sars-cov2
predictive factors of graft detachment following dmek

Conditions: Fuchs' Endothelial Corneal Dystrophy; Descemet Membrane Endothelial Keratoplasty; Pseudophakic Bullous Keratopathy; Graft Detachment

Summary: the aim of this study was to identify the predictive factors of graft detachment after descemet membrane endothelial keratoplasty (dmek) surgery. this retrospective study was conducted on patients aged 18 years, with fuchs' dystrophy (fecd) or pseudophakic bullous keratopathy (pbk), who were scheduled for dmek or triple-dmek (combined phacoemulsification and dmek surgery). patients with a history of surgery other than cataract surgery were excluded. the study was conducted between 2014 and 2022 and follow-up was for 3 months. the characteristics of patients with and without graft detachment following surgery were compared using logistic regression.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age with dmek surgery exclusion criteria: * all associated eye surgery other than cataract surgery * all existing anterior segment anomalies
propofol versus midazolam as premedication for preterm neonates with respiratory distress syndrome (rds)

Conditions: Respiratory Distress Syndrome

Summary: the aim of the study is to compare the intubation conditions among propofol and remifentanil versus midazolam and remifentanil in premature neonates with respiratory distress syndrome. at the same time, to show the group of drugs that could let the neonates with no residual sedation after the use of surfactant (the possibility of the premature neonates to be readily extubated after the use of surfactant).

it has been demonstrated that remifentanil, due to it its very short context-sensitive, has an interesting potential for use in premature neonates with respiratory distress syndrome. indeed, remifentanil allowed an adequate level of sedation and analgesia as well as rapid recovery after discontinuation. the aim of the present study was to compares the intubation conditions among propofol and remifentanil versus midazolam and remifentanil in premature neonates with respiratory distress syndrome.

Eligibility criteria:
inclusion criteria: * gestational age between 28-34 wk * clinical and radiological features compatible with respiratory distress syndrome that required elective tracheal intubation and surfactant therapy * hemodynamic stability before tracheal intubation * signature (parents) consent form exclusion criteria: * the presence of major congenital malformations * birth weigh less than 1000 g * previous use of opioid or other sedative drug for any reason * previous tracheal intubation * hemodynamic instability before the indication of tracheal intubation * refuse of the parents to enroll the neonate in the study protocol

Keywords: propofol midazolam neonate tracheal intubation
kirschner wire and pull-out wire fixation for the treatment of bony mallet finger

Conditions: Bony Mallet Finger

Summary: the objective of this report is to describe a new surgical technique for the treatment of bony mallet finger which involves the application of both kirschner wire and pull-out wire fixation. it is believed to decrease the risk of the complications.

from may 2003 to december 2008, we used kirschner wire and pull-out wire fixation to carry out 54 closed bony mallet finger in 54 patients. the bony mallet finger was applicated both kirschner wire and pull-out wire fixation.

Eligibility criteria:
inclusion criteria: 1. bony mallet finger; 2. patient had failed trials of nonsurgical treatment; 3. fracture involving more than 1/3 of the joint surface; 4. fragment displacement or subluxation of the dip joint. exclusion criteria: 1. tendinous mallet finger; 2. success of nonsurgical treatment; 3. comminuted fracture; 4. fracture involving at or less than 1/3 of the joint surface which could be successfully replaced with nonsurgical treatment.

Keywords: mallet finger extensor tendon kirschner wire fracture fixation
validation of the spasticity related quality of life questionnaire

Conditions: Spasticity, Muscle

Summary: the purpose of the study is to describe the psychometric properties (validity, reliability and responsiveness) of the sqol-6d instrument in the context of routine clinical treatment of upper limb spasticity.

the study qualifies as interventional not because of the use of an investigational product, but because the imposed specific data collection procedures include multiple questionnaire assessments and one on-site visit not necessarily part of routine clinical practice.

Eligibility criteria:
inclusion criteria: * currently resident in the uk * subjects with a diagnosis of uls * receiving a treatment at the enrolment visit, as part of their routine clinical management, aiming at reducing spasticity * sufficient grasp of english and cognitive ability to be able to understand the sqol-6d questions, give informed consent and complete the protocol requirements as judged by the investigator exclusion criteria: * the subject has already been included in the study * the subject, in the opinion of the investigator, would be unable to understand the questionnaire or to comply with the requirements of the study
expression levels of risc and microprocessor complex components in epithelial skin cancer

Conditions: Skin Cancer

Summary: micrornas (mirnas) are very small endogenous rna molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. mirnas bind to their target messenger rnas (mrnas), leading to cleavage or suppression of target mrna translation based on the degree of complementarity. mirnas have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. in the present study, the investigators examines the expression profiles of the microprocessor complex subunit dgcr8 and the risc components tarbp1, tarbp2, argonaute-1, argonaute-2 and pact in epithelial skin cancer and its premalignant stage.

patients with premalignant actinic keratoses, basal cell carcinomas and squamous cell carcinomas were included in the study. punch biopsies were harvested from the center of the tumors, from sites of healthy skin and a healthy control group. dgcr8, tarbp1, tarbp2, argonaute-1, argonaute-2 and pact mrna expression levels were detected by quantitative real-time reverse transcriptase polymerase chain reaction.

Eligibility criteria:
inclusion criteria: * epithelial skin cancer exclusion criteria: * other known previous malignancies

Keywords: basal cell carcinoma squamous cell carcinoma actinic keratosis microrna dicer drosha risc microprocessor complex argonaute dgcr8 tarbp